Skip to content
  • Pipeline
    • SurVaxM
  • Clinical Trials
  • About
    • Leadership Team
  • News
  • Contact
Menu
  • Pipeline
    • SurVaxM
  • Clinical Trials
  • About
    • Leadership Team
  • News
  • Contact
Pipeline
SurVaxM
Clinical Trials
About
Leadership Team
News
Contact
Read more about the article Roswell Park Research on Survivin Opens Up New Avenues for Cancer Immunotherapy
Cell.

Roswell Park Research on Survivin Opens Up New Avenues for Cancer Immunotherapy

  • Post author:web-designer
  • Post published:March 27, 2018
  • Post category:Uncategorized

Molecule can exist on tumor surface, suggesting new opportunities for CAR T and antibody-based therapies BUFFALO, N.Y. — New research from Roswell Park Comprehensive Cancer Center and MimiVax LLC shows…

Continue ReadingRoswell Park Research on Survivin Opens Up New Avenues for Cancer Immunotherapy

Recent Posts

  • Roswell Park Opens Phase 2B Randomized Clinical Trial of Promising Brain Cancer Immunotherapy
  • MimiVax, LLC Receives FDA Approval to Initiate a New Phase 2b Clinical Study for the Treatment of Newly Diagnosed Glioblastoma
  • MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients.
  • MimiVax Advances Toward New Clinical Trial for Brain Cancer Immunotherapy SurVaxM
  • MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. announce exclusive licensing agreement on SurVaxM for glioblastoma treatment in China

Recent Comments

    Archives

    • February 2022
    • November 2021
    • May 2020
    • November 2019
    • October 2019
    • May 2019
    • March 2018
    • August 2017
    • July 2016
    • September 2015
    • April 2015

    Categories

    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    MimiVax, LLC

    info@mimivax.com

    Elm & Carlton Streets
    Buffalo, NY 14263

    Back to top
    Twitter Linkedin Youtube